St Vincent’s Theranostics & Nuclear Medicine team commence innovative new trial You are here:HomeNewsroomAnnouncements St Vincent’s Theranostics & Nuclear Medicine team commence innovative new trial 04 Sep 2020 The team have commenced treatment on their first patient in a new clinical trial, targeting tumours in women with advanced breast cancer. Known as the C-BOBCAT trial, phase one represents the first in-human clinical trial investigating Cu64-SAR-Bombesin (SAR-BBN) in patents, in collaboration with Clarity Pharmaceuticals. This study will determine if the Cu64-SAR-Bombesin is a good target for a certain Breast Ca tumour – this will then aid future targeted therapy agents to actually treat these types of Cancers. With an initial cohort of 10 patients, phase 1 will determine if a larger trial will be beneficial. By being able to specifically target these particular breast cancer cells more accurately, it is expected that treatment benefits will include a reduction in treatment side-effects and a reduction of the number of treatments required.